Genetic variants of the drug-metabolizing enzyme CYP2D6 in Puerto Rican psychiatry patients: A preliminary report and potential implications for breast cancer patients

Puerto Rico Health Sciences Journal

Volumn 29, Issue 3, 2010, Pages 299-304

  González Tejera, Gloria ^a   Gaedigk, Andrea ^b   Corey, Susan ^a  

^a UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

^b CHILDREN S MERCY HOSPITAL   (United States)

Author keywords

AmpliChip; CYP2D6; Hispanic

Indexed keywords

CYTOCHROME P450 2D6;

ADULT; AGED; ALLELE; ARTICLE; BREAST TUMOR; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; ENZYMOLOGY; FEMALE; GENETIC VARIABILITY; GENETICS; HUMAN; MALE; MENTAL DISEASE; MIDDLE AGED; PILOT STUDY; PUERTO RICO;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; BREAST NEOPLASMS; COHORT STUDIES; CROSS-SECTIONAL STUDIES; CYTOCHROME P-450 CYP2D6; FEMALE; GENETIC VARIATION; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; PILOT PROJECTS; PUERTO RICO; YOUNG ADULT;

EID: 77957004076     PISSN: 07380658     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 2007;116: 496-526.
2. Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn- Schmiedeberg's Arch Pharmacol 2004;369: 23-37.
3. Zanger UM, Turpeinen M, Klein K, Schwab M. Functional pharmacogenetics/ genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem 2008;392: 1093-1098.
4. Akillu E, Persson I, Bertilsson L, et al. Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther 1996;278: 441-446.
5. McLellan RA, Oscarson M, Seidegard J, et al. Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians. Pharmacogenetics 1997;7: 187-191.
6. Bernal ML, Sinues B, Johansson I, et al. Ten percent of North Spanish individuals carry duplicated or triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine. Pharmacogenetics 1999;9: 657-60.
7. Rau T, Wohlleben G, Wuttke H, et al. CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study. Clin Pharmacol Ther 2004;75: 386-903
8. Lennard MS, Silas JH, Freestone S, Trevethick J. Defective metabolism of metoprolol in poor hydroxylators of debrisoquine. Br J Clin Pharmacol 1982, 14: 301-303.
9. Stearns V, Johnson MD, Rae JM, et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 2003; 95: 1758-64.
10. Higgins MJ, Stearns V. CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Res 2010;12: 7-15.
11. AmpliChip CYP450 test for in vitro diagnostic use [Internet]. [2007 Oct]. Roche. [cited 2009 Jan 31]. Available from: http://www.amplichip.us/documents/CYP450_P.I._US-IVD.pdf
12. Gaedigk A, García MI, Pearce RE, et al. Discovery of the non-functional CYP2D6&z.ast;31 allele in Spanish, Puerto Rican and US Hispanic populations. Eur J Clin Pharmacol 2010 May 16. [Epub ahead of print].
13. Gaedigk A, Simon SD, Pearce RE, et al. The CYP2D6 activity score: Translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther 2008;83: 234-242.
14. Gaedigk A, Bradford LD, Marcucci KA, Leeder JS. Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans. Clin Pharmacol Ther 2002;72: 76-89.
15. Luo HR, Gaedigk A, Aloumanis V, Wan YJ. Identification of CYP2D6 impaired functional alleles in Mexican Americans. Eur J Clin Pharmacol 2005;61: 797-802.
16. Chou WH, Yan FX, Robbins-Weilert DK, et al. Comparison of two CYP2D6 genotyping methods and assessment of genotype-phenotype relationships. Clin Chem 2003;49: 542-551.
17. Kohlrausch FB, Gama CS, Lobato MI, et al. Molecular diversity at the CYP2D6 locus in healthy and schizophrenic southern Brazilians. Pharmacogenomics 2009;10: 1457-1466.
18. Raimundo S, Fischer J, Eichelbaum M, et al. Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6. Pharmacogenetics 2000;10: 577-581.
19. Toscano C, Klein K, Blievernicht J, et al. Impaired expression of CYP2D6 in intermediate metabolizers carrying the &z.ast;41 allele caused by the intronic SNP 2988G>A: Evidence for modulation of splicing events. Pharmacogenet Genomics 2006;16: 755-766.
20. Cai WM, Nikoloff DM, Pan RM, et al. CYP2D6 genetic variation in healthy adults and psychiatric African-American subjects: Implications for clinical practice and genetic testing. Pharmacogenomics J 2006;6: 343-350.
21. Gaedigk A, Ndjountché L, Leeder JS, Bradford LD. Limited association of the 2988G>A single nucleotide polymorphism with CYP2D6&z.ast;41 in black subjects. Clin Pharmacol Ther 2005;77: 228-230.
22. Sistonen J, Fuselli S, Palo JU, et al. Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales. Pharmacogenet Genomics 2009;19: 170-179.
23. Ruaño G, Duconge J, Windemuth A, et al. Physiogenomic analysis of the Puerto Rican population. Pharmacogenomics 2009;10: 565-577.
24. Marez D, Legrand M, Sabbagh N, et al. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: Characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 1997;7: 193-202.
25. Allorge D, Bréant D, Harlow J, et al. Functional analysis of CYP2D6.31 variant: Homology modeling suggests possible disruption of redox partner interaction by Arg440His substitution. Proteins 2005;59: 339-46.
26. Rowland P, Blaney FE, Smyth MG, et al. Crystal structure of human cytochrome P450 2D6. J Biol Chem 2006;281: 7614-7622.
27. Basic HHS Policy for Protection of Human Research Subjects [Internet]. [updated 2005 June 23]. National Institutes of Health: Office of Human Subjects Research [cited 2010 May 4]. Available from: http: //ohsr. od.nih.gov/guidelines/45cfr46.html
28. Goetz MP, Knox SK, Suman VJ, et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 2007;101: 113-121.
29. Newman WG, Hadfield KD, Latif A, et al. Impaired tamoxifen metabolism reduces survival in familial breast cancer patients. Clin Cancer Res 2008;14: 5913-5918.
30. Schroth W, Antoniadou L, Fritz P, et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 2007;25: 5187-5193.
31. Kiyotani K, Mushiroda T, Sasa M, et al. Impact of CYP2D6&z.ast;10 on recurrence- free survival in breast cancer patients receiving adjuvant tamoxifen therapy. Cancer Sci 2008;99: 995-999.
32. Kiyotani K, Mushiroda T, Imamura CK, et al. Significant Effect of Polymorphisms in CYP2D6 and ABCC2 on Clinical Outcomes of Adjuvant Tamoxifen Therapy for Breast Cancer Patients. J Clin Oncol 2010;28: 1287-1293.
33. Hoskins JM, Carey LA, McLeod HL. CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer 2009;9: 576-586.
34. Wegman P, Elingarami S, Carstensen J, et al. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res 2007;9: R7.
35. Nowell SA, Ahn J, Rae JM, et al. Association of genetic variation in tamoxifen- metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Research and Treatment 2005;91: 249-258.
36. Ramón y Cajal T, Altés A, Paré L, et al. Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment. Breast Cancer Res Treat 2010;119: 33-38.
37. Borges S, Desta Z, Jin Y, et al. Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients. J Clin Pharmacol 2010;50: 450-458.